Compare VanEck Gold Miners ETF (GDX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Merck & Co., Inc. — how do they compare? VanEck Gold Miners ETF trades at $89 (market cap $25.65B), while Merck & Co., Inc. trades at $144.68 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 13.7× VanEck Gold Miners ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Merck & Co., Inc. for 98 Days on average.
| GDX | MRK | |
|---|---|---|
Market Cap | $25.65B | $351.28B |
Volume | 16,534,046 | 7,969,665 |
52-Week High | $115.84 | $156.43 |
52-Week Low | $68.28 | $82.49 |
Typical Hold Time | 76 Days | 98 Days |
Sector | — | Health |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.31, up 4.51% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces headwinds from rising interest rates pressuring dividend stocks and a recent sell-off in metals. Support levels are clustered between $84 and $86, while resistance sits near $87 to $89. Recent news highlights institutional selling by firms like Allworth Financial and HB Wealth Management, though Ameritas Advisory Services increased its stake.
The outlook for GDX is cautious due to bearish technicals and macroeconomic pressures on gold miners. Opportunities exist if gold prices rebound, but risks include persistent rate hikes and volatility in commodity markets. Investors should weigh the ETF's leverage to gold against operational risks in the mining sector.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
